Company news

Pyxis Oncology, Inc. news in 2025

Pyxis Oncology, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin in Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma

December 19, 2025

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

December 18, 2025

Pyxis Oncology to Participate in Upcoming Investor Conferences

November 3, 2025

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

November 3, 2025

Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

October 13, 2025

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

October 9, 2025

Maxion Therapeutics Appoints Joel Edwards as Chief Business Officer

October 1, 2025

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 30, 2025

Pyxis Oncology to Participate in September Investor and Industry Conferences

August 21, 2025

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

August 14, 2025

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

May 14, 2025

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

April 25, 2025

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

April 2, 2025

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

March 25, 2025

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 18, 2025

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

March 3, 2025

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

February 26, 2025

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

February 3, 2025

Decks in 2025